(Q34608222)

English

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

David Cunningham

5

object named as

D Cunningham

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

A F C Okines

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

A R Norman

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

P McCloud

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Y-K Kang

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

27 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1529-1534

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Capecitabine: preclinical pharmacology studies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Clinical pharmacokinetics of capecitabine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Answering patients' needs: oral alternatives to intravenous therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP047

21 January 2018

Identifiers

10.1093/ANNONC/MDP047

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34608222&oldid=1556849956"